| Company Name: |
BOC Sciences |
| Tel: |
1-631-485-4226; 16314854226 |
| Email: |
info@bocsci.com |
|
| | ORY-1001(trans) Basic information |
| Product Name: | ORY-1001(trans) | | Synonyms: | ORY-1001(trans);trans-N1-((1R,2S)-2-Phenylcyclopropyl)cyclohexane-1,4-diamine dihydrochloride;ORY-1001 dihydrochloride;Iadademstat dihydrochloride;RO 7051790,RG 6016,Iadademstat dihydrochloride,Histone Demethylase,Iadademstat,RO7051790,inhibit,RG6016,Inhibitor,ORY1001,RO-7051790,ORY 1001,ORY-1001,RG-6016;(1r,4R)-N1-((1R,2S)-2-phenylcyclopropyl)cyclohexane-1,4-diamine;ORY-1001(Ladademstat);ORY1001 HCl salt | | CAS: | 1431303-72-8 | | MF: | C15H23ClN2 | | MW: | 266.81 | | EINECS: | | | Product Categories: | | | Mol File: | 1431303-72-8.mol |  |
| | ORY-1001(trans) Chemical Properties |
| storage temp. | Store at -20°C | | solubility | Water: 57.75 mg/mL (190.42 mM and warming); DMSO: 0.69 mg/mL (2.28 mM and warming) | | form | Solid | | color | White to off-white |
| | ORY-1001(trans) Usage And Synthesis |
| Uses | Iadademstat (ORY-1001) dihydrochloride is a selective irreversible lysine (K)-specific demethylase 1A (KDM1A/LSD1) inhibitor. | | in vivo | Iadademstat reduces AML tumor growth in mice and rat xenografts and increases survival time in a disseminated model of T-ALL[1]. | | References | [1] Maes T, et al. KDM1 histone lysine demethylases as targets for treatments of oncological and neurodegenerative disease. Epigenomics. 2015;7(4):609-26. doi: 10.2217/epi.15.9. DOI:10.2217/epi.15.9
[2] Tamara Maes, et al. ORY-1001, a Potent and Selective Covalent KDM1A Inhibitor, for the Treatment of Acute Leukemia. Cancer Cell. 2018 Mar 12;33(3):495-511.e12. DOI:10.1016/j.ccell.2018.02.002 |
| | ORY-1001(trans) Preparation Products And Raw materials |
|